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ABSTRACT 
Introduction 
There are no randomised control trials of statin therapy in patients with severe 
bronchiectasis, chronically infected with Pseudomonas aeruginosa.  
 
Methods 
32 patients chronically infected with P. aeruginosa were recruited in this double blind 
cross over RCT. 16 patients were recruited in each arm, given atorvastatin 80mg or 
placebo for 3months, followed by a washout period for 6weeks, crossed over and 
administered the alternative therapy for 3months.   
 
Results 
27 patients completed the study. Atorvastatin did not significantly improve the 
primary endpoint of cough as measured by Leicester Cough Questionnaire [mean 
difference=1.92, 95% CI for difference (-0.57, 4.41), p=0.12]. However, atorvastatin 
treatment resulted in improved St Georges Respiratory Questionnaire (-5.62points, 
p=0.016), reduced serum CXCL8 (p=0.04), TNF (p=0.01) and ICAM1 (p=0.04). 
There was a trend towards improvement in serum CRP and serum neutrophil counts 
(p=0.07 and p=0.06 respectively).  
 
In vitro, we demonstrated that atorvastatin 10µM reduced fMLF induced upregulation 
of CD11b expression and changes in calcium flux reflecting an ability to decrease 
neutrophil activation. 
 
Conclusion 
We demonstrated that atorvastatin reduced systemic inflammation and improved 
quality of life in bronchiectasis patients infected with P. aeruginosa. These effects 
may be due to an ability of atorvastatin to modulate neutrophil activation.  
 
Word count (abstract): 196 
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TEXT 
Introduction 
Bronchiectasis is characterized by permanently damaged airways and persistent 
excessive neutrophilic airways inflammation, yet despite this, there is ongoing 
bacterial colonization. The kinetics of the establishment of infection and its 
relationship with the subsequent inflammatory response is poorly understood (1). The 
severity of the inflammatory response depends on the interplay between pro-
inflammatory mediators, which are up regulated, and anti-inflammatory mediators and 
inhibitors, which are released to limit its extent and duration (2).  We hypothesize that 
there is a failure of resolution of inflammation in bronchiectasis and propose a role for 
anti-inflammatory therapy in bronchiectasis.  
 
Statins have been used for more than two decades for primary prevention of 
cardiovascular disease. However, over the last few years, studies in both animal and 
human models have established that statins have pleiotropic effects, which include 
modulation of the innate and adaptive immune system and anti-inflammatory 
properties (3,4). The mechanisms by which statins modulate inflammation remain 
incompletely defined.  
  
We have recently demonstrated that 6 months treatment with atorvastatin, 80 mg once 
daily, reduced cough, enhanced sputum neutrophil apoptosis and reduced serum 
CXCL8 (also called interleukin (IL) 8) when used in the stable state in moderately 
severe bronchiectasis patients not chronically infected with Pseudomonas aeruginosa 
(5). These encouraging results prompted a trial of atorvastatin treatment in a group of 
patients with more severe bronchiectasis, chronically infected with Pseudomonas 
aeruginosa. 
 
We hypothesized that prolonged statin treatment would improve patients’ symptoms 
as a consequence of the anti-inflammatory properties of the drug. The aims of this 
study were: 
i. To assess whether atorvastatin 80 mg once daily for 3 months could reduce 
cough severity and inflammation in bronchiectasis patients chronically 
infected with Pseudomonas aeruginosa. 
ii. To assess the mechanisms (in vitro studies) by which statins may modulate 
neutrophilic inflammation in bronchiectasis patients. 
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Methods 
Study population 
We recruited patients aged 18–79 years who were receiving treatment at the Royal 
Infirmary of Edinburgh, UK. Inclusion criteria were chronic cough and sputum 
production when clinically stable; two or more exacerbations in the preceding year; 
chronic infection with Pseudomonas aeruginosa (defined as two or more isolates of P 
aeruginosa while clinically stable, that is, no exacerbations requiring antibiotics- in 
the 12 months before the study) and bronchiectasis confirmed on chest CT, by a 
radiologist. For diagnosis on CT, bronchial dilatation had to be present 
(bronchus:arterial ratio >1). Bronchiectasis Severity Index was calculated on all 
patients (6).  
We excluded: current smokers or former smokers who had stopped smoking less than 
1year previously, those with a greater than 15 pack-year history, or those with 
predominant emphysema on CT scan; cystic fibrosis; active allergic 
bronchopulmonary aspergillosis; active tuberculosis; poorly controlled asthma; 
pregnant or breastfeeding; known allergy to statins; those currently on statins or who 
had used them within the previous year; active malignant disease; chronic liver 
disease; on long-term oral macrolides (because of the known interaction with statins); 
active inflammatory disease (arthritis, bowel disease) requiring disease modifying 
agents.  
West of Scotland research ethics committee (14/WS/1080) approved the study. All 
patients gave written informed consent. 
Randomisation and masking 
We randomly allocated patients to receive either high-dose atorvastatin (80mg) or 
placebo (lactose), given orally once a day for 3months. Following this, patients had a 
6weeks washout period (as half life of atorvastatin is 14-20 hours).  Patients were then 
crossed over and commenced on the opposite treatment. Although, the placebo was 
not matched to atorvastatin in appearance, the study medicines were dispensed by and 
returned to pharmacy, hence allocation concealment was maintained always from the 
study investigators. Random allocation sequence in block randomisations of four was 
done. 
Outcomes 
The primary outcome measure was reduction in perceived cough at 3months 
compared with baseline, measured by the Leicester Cough Questionnaire (LCQ) 
score. Secondary outcomes included: forced expiratory volume in 1s (FEV1), forced 
vital capacity (FVC); incremental shuttle-walk test; qualitative and quantitative 
sputum bacteriology; frequency of exacerbations; health-related quality of life 
(SGRQ), assessment of sputum neutrophil numbers and apoptosis; neutrophil 
activation in the airway, measured by sputum myeloperoxidase, free elastase activity, 
and CXCL8; systemic inflammation, measured by white-blood-cell count, C-reactive 
protein, and erythrocyte sedimentation rate; other markers of systemic inflammation, 
including concentrations of interleukins 1β, 6, 8, 10, 12p70, tumour necrosis factor 
(TNF), and intercellular adhesion molecule (ICAM)1; and safety of treatment. 
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Procedures 
I. Clinical Studies 
We conducted assessments at baseline, 3months, 4.5months and at 7.5months 
(duration of treatment 3months as this was a cross over study). If study subjects had 
an exacerbation, they were reviewed and assessed at the beginning and end of 
exacerbation. 
 
We assessed cough with the LCQ. This questionnaire is a 19-item, self-completed, 
quality-of-life measure of chronic cough, with scores from 3 to 21 (a lower score 
indicates more severe cough). The minimum clinically important difference in LCQ 
score is 1·3 units (7-9). 
We measured prebronchodilator FEV1, FVC, and FEV1:FVC by spirometry, followed 
by an incremental shuttle-walk test; an externally paced, 10 m, field-walking test, 
(10). Health-related quality of life was assessed with the St George’s Respiratory 
Questionnaire, which  is a 50-item self-administered test with a total score ranging 
from 0 to 100 (a higher score indicates poorer health-related quality of life). The 
minimum clinical important difference in SGRQ score is 4 units (11). 
We induced sputum with hypertonic (3%) saline for 10 minutes. Sputum was induced 
in all patients to ensure that appropriate samples were obtained and that there was no 
patient to patient variablity (i.e. patients not producing sputum at the time of study 
visit or patients producing inadequate samples). Samples were used for bacteriological 
analysis and neutrophil assessments (12). We used 1mL of the sputum sample for 
qualitative and quantitative microbiological analyses. Rest of the sample was used to 
assess total cell numbers and analysis of the activity of myeloperoxidase, free 
neutrophil elastase, and CXCL8.  
We took 30mL of venous blood to obtain a full-blood count, erythrocyte 
sedimentation rate, C-reactive protein, urea, electrolytes, creatine kinase and liver-
function tests. Serum was stored for measurement of proinflammatory and anti-
inflammatory cytokines and chemoattractants by cytometric bead array (BD 
Biosciences) and ELISA’s as per manufacturers protocols (CXCL8 and ICAM 1- 
R&D systems). 
We assessed patients for the presence or absence of side-effects at all study visits. If 
activity of alanine aminotransferase was greater than five times the normal value, or 
concentrations of creatine kinase were greater than three times the upper limit of 
normal, we stopped the assigned study treatment. We recorded all side-effects on a 
patient diary card. We defined exacerbations according to British Thoracic Society 
guidelines (increased cough, increased sputum volume and/or purulence and feeling 
systemically unwell) and treated them according to baseline sputum bacteriological 
findings and administered 14 days of oral or intravenous antibiotic treatment as per 
British Thoracic Society guidelines (13). If their study assessment days coincided 
with an ongoing exacerbation, patients were reviewed and assessed when stable 
within 2 weeks of completing the antibiotic therapy. Statins were not stopped during 
an exacerbation. 
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II. In vitro studies 
Isolation of neutrophils: Granulocytes were isolated by dextran sedimentation and 
discontinuous Percoll gradient, as described, from blood taken from healthy 
volunteers (14).  
Neutrophil activation: As there was a reduction in serum ICAM-1 (see results 
section), we investigated the role of statins in CD11b expression, which functionally 
regulates neutrophil adhesion. We also assessed expression of CD62L which is key 
for leukocyte rolling prior to migration. After isolation of neutrophils, they were 
treated with atorvastatin at varying concentrations. FITC-labelled CD11b antibodies 
and PE-labelled CD62L antibodies were added and samples analysed by flow 
cytometry (15). 
Intracellular calcium flux: As Ca2+ ions serve as important second messengers in 
signal transduction in neutrophils, we investigated the role of statins in regulating 
neutrophil calcium flux.  Neutrophils were loaded with fura-2/AM (Invitrogen). 
Intracellular calcium flux was quantified in response to fMLF, with or without a 
30min pretreatment with atorvastatin at varying concentrations (16).  
 
 
Statistical analysis 
Based on previous studies, we know the mean (SD) pre-post change in placebo is -
0.23 (1.1) and that a difference of 1.3 Units is a clinically relevant difference (7-9). 
Using a two sided paired test, with 5% level of significance, 80% power, mean of 
differences of 1.3, the sample size was 26. To account for an approximate 20% drop 
out we would recruit 32 patients. 
We analyzed the study with modified intention-to-treat analysis. For demographic and 
clinical variables, we presented data as mean (standard deviation) for continuous 
variables and number (%) for categorical variables, unless otherwise stated. To 
examine continuous variables we calculated the change during the atorvastatin period 
[either baseline to 3 month or 4.5 months to 7.5 months] and compared this to the 
change during the placebo period [either 4.5 months to 7.5 months or baseline to 3 
months] by paired t test, we did not take the period into account. To compare the 
proportion of patients with either clinical improvement (measured by the LCQ) or 
quality-of-life gains (measured by the SGRQ), we used a McNemars test. We 
compared categorical data between groups, with the χ2 test. Statistical significance 
was taken to be <0.05. We analysed all data with SAS version 9.4 and Graphpad 
Prism version 6.0f. 
 
 
 
 
Results 
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32 patients were randomized to receive treatment: 16 received Atorvastatin 80mg and 
16 received placebo for 3 months.  
 
Figure 1. Consort diagram of recruitment. 
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Baseline demographics are shown in table 1. Data is presented as mean (standard 
error of mean).   
 
 
Atorvastatin-Placebo 
N=16 
Placebo- Atorvastatin 
N=16 
Age (years) 62.3 (2.4) 67.8 (2.5) 
Gender (Female%) 66% 66% 
BMI (Kg/m2) 25.2 (1.1) 25.9 (0.7) 
BSI 11.4 (0.9) 10.9 (0.9) 
Smoking status 
 
Non smoker 
Ex smoker 
 
 
13 (81%) 
3 (19%) 
 
 
11 (69%) 
5 (31%) 
Cause of bronchiectasis 
 
Idiopathic 
Post infection 
Rheumatoid Arthritis 
Ulcerative colitis 
 
 
11 (69%)  
3 (19%) 
0 
2 (12%) 
 
 
12 (75%) 
2 (12%) 
1 (6%) 
1 (6%) 
Spirometry 
 
FEV1 (L) 1.7 (0.2) 1.8 (0.2) 
FEV1 (% predicted) 54.6% (9.4) 58.4% (6.5) 
FVC (L) 2.5 (0.2)  2.8 (0.2) 
FVC (% predicted) 62.1% (10.2) 72.9% (7.8) 
Sputum microbiology 
 
P. aeruginosa* 
Haemophilus influenzae 
Gram negative bacteria 
Streptococcus 
pneumoniae 
MNF 
 
 
 
10 (64%) 
2 (12%) 
2 (12%) 
1 (6%) 
 
1 (6%) 
 
 
 
9 (57%) 
0 
2 (12%) 
0 
 
5 (31)% 
 
COPD 0 1 (6%) 
Asthma 4 (25%) 5 (31%) 
ABPA (inactive) 2 (12%) 2 (12%) 
Previous malignancy 4 (25%) 5 (31%) 
Hypertension 2 (12%) 5 (31%) 
ICS 11 (69%) 11 (69%) 
Long term oral steroids 0 0 
Long term antibiotic for 
chest 
5 (31%) 
(3 on inhaled tobramycin, 
2 on inhaled gentamicin) 
3 (19%) 
(2 on inhaled gentamicin, 
1 on inhaled tobramycin) 
Table 1. Baseline demographics; ABPA= allergic bronchopulmonary aspergillosis; 
BMI= body mass index; COPD= chronic obstructive pulmonary disease; ICS= 
inhaled corticosteroids; MNF= mixed normal flora.*Some patients did not isolate P 
aeruginosa at the start of the study, but met the criteria being chronically infected 
with P aeruginosa (defined as two or more isolates of P aeruginosa while clinically 
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stable in the 12 months before the study), thus could be co-infected with other micro 
organisms. 
 
Primary outcome 
There was no evidence of a difference in the mean LCQ change in patients treated 
with atorvastatin compared to placebo [mean difference =1.92, 95% CI for difference 
(-0.57, 4.41), p=0.125]. During the active period 12/27 participants showed a 
clinically relevant improvement in the LCQ (≥ 1.3 Units), compared with 5/27 in the 
placebo group, 10 improved only while receiving atorvastatin, 3 only while receiving 
placebo and 2 during both periods. However, using a McNemars test there is no 
evidence of a difference in the distribution of the discordant results at the 5% level, 
p=0.092.  
 
Secondary outcomes 
27 patients completed the study and were included in the modified intention to treat in 
the secondary outcome analysis.  
 
Quality of life 
There was a significant difference in the change in SGRQ total score on atorvastatin 
compared to placebo [mean difference = -5.62, 95% CI for difference (-10.13, -1.13), 
p=0.016]. There was an improvement in the activity domain of the SGRQ in patients 
on atorvastatin compared to placebo [mean difference = -5.7, 95% CI for difference (-
10.3, -1.1), p=0.02]. Data for other domains not shown. 
 
Serum inflammatory markers 
There was evidence of a significant difference in the change in serum IL8 (CXCL8;  
p=0.04), TNF (p=0.01) and ICAM1 (p=0.04) at the end of treatment, in atorvastatin 
compared to placebo (figure 2, table 2 and table E1- online supplement). There was 
no significant change in serum IL1beta (p=0.3), IL6 (p=0.3), IL10 (p=0.6) or IL12p70 
(p=0.1). 
The mean change in CRP and serum neutrophil counts between the two treatments 
showed a trend towards reduction in the atorvastatin group but failed to reach 
statistical significance (p=0.07 and p=0.06 respectively). There was no evidence of a 
significant difference in the change in ESR levels in atorvastatin compared to placebo 
(p=0.7) at the end of treatment (table 2). 
 
Sputum microbiology 
In the atorvastatin group, 94% had a positive sputum sample with bacteria at the 
beginning of treatment and 77% at the end of treatment and in the placebo group, the 
numbers were 69% and 75% respectively. Less patients had a positive sputum sample 
in the atorvastatin group compared to the placebo group at the end of treatment 
(comparison within groups); p=0.03. 
In the atorvastatin group, in patients that remained infected, the mean (SEM) 
quantitative bacterial count at the beginning of treatment was 7.6 (0.16) log units and 
at the end of treatment was 7.2 (0.26) log units; in the placebo group, numbers were 
7.3 (0.27) log units and 7.3 (0.24) log units, respectively. There was no significant 
decrease in bacterial load between the groups at the end of treatment, p=0.1.  
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Sputum inflammatory markers 
There was no change in the number of apoptotic neutrophils (p=0.9), eosinophils, 
basophils or monocytes (table 2). There was no statistical improvement in sputum 
CXCL8, myeloperoxidase or free neutrophil elastase (table 2).   
Lung physiology and exercise tolerance 
There was no improvement with atorvastatin in FEV1, FVC, or FEV1:FVC, or 
incremental shuttle walk test (table 2).  
 
Cholesterol 
There was a statistically significant improvement in cholesterol levels mean 
difference -1.6 mmol/l, p <0.0001, in the atorvastatin group. 
 
Exacerbations requiring antibiotics 
11/27 (41%) had exacerbations during both periods. During the placebo phase 7/27 
(26%) had exacerbations and during the active phase 9/27 (33%) had exacerbations. 
There was no improvement in exacerbations with atorvastatin treatment. 
 
Adverse events 
There was no significant difference in the creatinine kinase or alanine 
aminotransferase levels while on the statin (table 2). 3 patients dropped out when they 
were on the active treatment and 2 patients while they were on placebo group dropped 
out. Of the 3 patients in the active group that dropped out, 1 patient had to withdraw 
as he had a transient ischaemic attack (unrelated to the study drug) and two withdrew 
for personal reasons. Both patients in the placebo group dropped out due to 
headaches. No other adverse events were recorded during the study.  
 
 
Figure 2. Serum inflammatory markers; A. Serum CXCL8; B. Serum TNF and Serum 
Intercellular adhesion molecule (ICAM)-1, showing mean change and standard error 
of mean.  
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Mean 
 
95% CI 
 
p-value 
 
Induced sputum 
 
 
 
 
Apoptotic 
neutrophil (%) 
0.111 
 
-11.328 11.550 0.98 
 
Eosinophil (%) 0.519 -0.161 1.198 0.13 
Monocytes (%) 0.074 -0.913 1.061 0.88 
Neutrophils (%) 22.000 -29.652 73.652 0.39 
Pulmonary 
physiology 
FEV1 (L) 0.007 -0.117 0.131 0.90 
FVC (L) -0.058 -0.106 0.223 0.47 
FEV1:FVC Ratio -0.013 -0.056 0.031 0.55 
  Blood markers 
 
 
 
CXCL8 (pg/ml) -27.96 -54.95 -0.96 0.04 
TNF  (pg/ml) -14.24 -25.63 -2.85 0.01 
ICAM 1 (ng/ml) -126.67 -249.61 -3.72 0.04 
ALT (IU/L) 2.769 -3.133 8.672 0.34 
Urea (mmol/L) -0.412 -1.163 0.340 0.27 
Creatinine (µmol/L) -3.385 -9.216 2.446 0.24 
CK (U/L) 0.125 -53.450 53.700 1.0 
Cholesterol 
(mmol/L) -1.642 -2.168 -1.117 <0.0001 
CRP (mg/L) -14.104 -29.561 1.353 0.07 
ESR (mm/hr) -1.272 -10.889 8.344 0.76 
White blood cells 
(X109/L) -0.485 -1.338 0.368 0.25 
Neutrophils 
(X109/L) -0.602 -1.246 0.041 0.06 
Eosinophils(X109/L) 0.060 -0.042 0.162 0.23 
Basophils (X109/L) -0.007 -0.068 0.053 0.80 
Lymphocytes 
(X109/L) 0.065 -0.184 0.314 0.6 
Monocytes (X109/L) -0.013 -0.138 0.111 0.83 
 
 
Sputum markers 
 
CXCL8 (pg/ml) 
-7255.300 
-
21249.100 6738.400 0.3 
Myeloperoxidase 
(ng/ml) 
-
16709.400 
-
47540.700 14121.800 0.27 
Neutrophil elastase 
(ng/ml) 12144.600 
-
28571.500 52860.700 0.54 
Exercise capacity 
 
ISWT (metres) 
 
5.2 
 
-45.6 
 
56.1 
 
0.62 
 
Table 2. Results comparing the change on active versus placebo. ALT= alanine 
aminotransferase; CK= creatinine kinase; CRP= c reactive protein; CXCL8= 
Interleukin 8; FEV1= forced expiratory volume in 1 sec; FVC= forced vital capacity; 
ICAM1= intercellular adhesion molecule 1; ISWT= Incremental shuttle walk test; 
TNF = Tumour necrosis factor. 
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In vitro studies 
(i) Neutrophil activation 
As there was a reduction in serum ICAM-1, we investigated the role of statins in  
CD11b expression, which functionally regulates neutrophil adhesion and found that 
atorvastatin 10µM significantly reduced fMLF-induced peripheral blood neutrophil 
activation (p=0.03). This effect was comparable to a known potent and competitive 
inhibitor of formyl peptide receptor-1 (FPR1), cyclosporin H; p=0.03 (figure 3a&c). 
There was however no effect of atorvastatin 10µM on CD62L shedding (figure 3b).  
 
 
Figure 3a-c. fMLF stimulated serum neutrophils increased CD11b expression and this 
was significantly reduced when neutrophils were pre treated with 10µM of 
atorvastatin (**p=0.02). This was comparable to the positive control in the 
experiment CSH- known FPR1 receptor antagonist, *p=0.03. ; 3b. There was no 
effect on fMLF induced CD62L shedding. Abbreviations: CSH= cyclosporin H, 
Ator=atorvastatin. 
 
(ii) fMLF induced Ca2+ flux 
fMLF (10nM) induced a significant rise in calcium flux. This fMLF induced 
increase in cytoplasmic Ca2+ was significantly reduced by pre-incubation (30 
min) with atorvastatin (area under the curve is 0.7 for atorvastatin 10µM 
(standard error 0.04, p<0.0001) in a concentration-dependant manner (figure 4a & 
b).   
 
 
Figure 4a & b. fMLF increases [Ca2+] flux when added to serum neutrophils.  This 
was reduced by atorvastatin in a concentration dependent manner, when neutrophils 
were pre treated with atorvastatin, prior to adding fMLF. Ator= atorvastatin. 
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Discussion 
This proof of concept study showed that although administration of atorvastatin for 
three months, to bronchiectasis patients infected with P. aeruginosa, did not reduce 
cough, it did improve quality of life, as assessed by the St George’s respiratory 
questionnaire. In addition, this treatment reduced systemic inflammation, evidenced 
by a statistically significant reduction in serum CXCL8, TNF and ICAM1, at the end 
of statin treatment for 3 months. A trend towards reduction of serum neutrophil count 
and C-reactive protein was also observed, but this failed to reach statistical 
significance. Furthermore, atorvastatin treatment resulted in a statistically significant 
reduction in the number of patients with pulmonary bacterial colonisation, compared 
to placebo, although no significant change in mean bacterial load was observed. This 
is perhaps secondary to the anti inflammatory effect alone of statins. There was no 
improvement in spirometry, exercise capacity or sputum inflammatory markers. 
 
Our current study didn’t show statistical evidence to achieving its primary end point, 
cough reduction. We have previously shown that atorvastatin reduced cough severity 
as measured by the LCQ, when administered to 60 bronchiectasis patients infected 
with microorganisms other than P. aeruginosa for 6months (5). However, in this 
current study treatment was for only 3months, the study group is smaller in size, and a 
more severe group of bronchiectasis patients. The proof of concept study period was 
shorter to check its safety in this group with more severe bronchiectasis.  
 
Although the LCQ did not change, there was an improvement in the quality of life, as 
measured by the St Georges respiratory questionnaire. There was an improvement in 
the activity domain in the SGRQ score. The LCQ focuses on cough related quality of 
life whereas SGRQ is a more generic respiratory quality of life score that assesses 
symptoms, activity and impact. The mechanism why statins improved the activity 
domain is unknown. 
 
It has been well established that statins can reduce the expression and function of 
molecules on the leukocytes surface (17). Statin sensitive cellular functions include 
adhesion, chemotaxis, and release of superoxide anion (O2-) and cytokines (18-20). 
Another anti-inflammatory effect of statins on monocytes and macrophages was the 
decrease of the expression of intercellular adhesion molecule-1 and the secretion of 
IL-6, induced by lipopolysaccharides (LPS) (21). The presence of inflammation and 
endotoxin in the blood tends to up-regulate leukocyte–endothelial interactions (22). 
This is a step-wise process requires that first leukocytes roll along the vascular 
endothelium mediated by CD62L followed by firm adhesion and migration into tissue 
mediated by CD11b.  Firm adhesion involves the β2 integrins CD11b and CD18, 
which are expressed on leucocytes and bind to the ICAM-1 on the vascular 
endothelium (23).  
 
As there was an atorvastatin-mediated reduction of ICAM-1 in our study, we explored 
the role of statins on the expression of CD11b and CD62L. Upon activation with 
fMLF, there was an increase in CD11b expression and a decrease in CD62L 
expression, indicative of leukocyte activation and consequently selectin shedding. 
Atorvastatin significantly reduced fMLF-induced neutrophil activation and 
upregulation of CD11b. However, atorvastatin did not attenuate the shedding of 
CD62L. This might be explained if the inhibitory effect of statins on activated 
neutrophils is mediated by blocking expression of the Mac-1 integrin subunit CD11b, 
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rather than by inhibition of integrin activation. Similar findings were observed by 
Aparecida and colleagues in a study investigating the role simvastatin on inflamed 
neutrophil adhesive properties (24).  
 
Ca2+ ions serve as important second messengers in signal transduction, leading to the 
activation of downstream molecules (25).  Cytoplasmic levels of Ca2+ can increase 
either from release from internal calcium stores or by entry from outside the cell via 
calcium channels, leading to the rapid activation of molecules that promote function 
(26). fMLF is recognized by neutrophils and is a potent neutrophil chemoattractant. 
fMLF, upon binding to its heterotrimeric G protein-coupled receptor, initiates 
signalling cascades that activate multiple pathways (27).  In neutrophils, stimulation 
by agonists that bind to the fMLF receptor, trigger increases in intracellular Ca2+. 
Elevation of intracellular free Ca2+ levels or mobilization of intracellular Ca2+ stores 
promotes neutrophil longevity (28). The current study demonstrates that atorvastatin 
can reduce fMLF-mediated calcium flux. The implication of this in bronchiectasis 
could be that statins, by decreasing calcium flux, reduce the longevity of neutrophils, 
with consequences for the persistence of the characteristic neutrophil inflammation 
(29). Whether statins can regulate extracellular Ca2+mobilization, by activation of 
store operated calcium influx receptors, or  mobilise Ca2+ by release from intracellular 
stores, via G-protein coupled receptors or tyrosine kinase receptors, remains to be 
determined. 
 
There was no reduction in sputum inflammatory markers and this was in keeping with 
our previous study (5). Similar results were demonstrated by Llewellyn- Jones, where 
pretreatment with indomethacin led to a reduction in neutrophil chemotaxis but had 
no effect on sputum myeloperoxidase or free elastase activity (29). Further 
mechanistic studies are needed to assess the immunomodulatory effects of statins on 
neutrophils. 
 
One of the major side effects of statins is myositis and liver function abnormality. 
There were no patients who had to withdraw because of myositis induced leg pain or 
deranged alanine aminotransferase. Headaches (6%) were the most important cause of 
dropouts although this was noted only in the placebo group. There were no other 
adverse events recorded in the study, other than the ones mentioned which 
necessitated patients to drop out. 
 
 
Limitations 
This study was not powered for the secondary end points. Another limitation was that 
the active and placebo drugs were not matched. However, the researcher was not 
aware of the study drugs administered to the patients as these were directly dispensed 
by pharmacy to the patients. The proof of concept study was short over 3 months and 
longer treatment, 6 months or longer, may be needed. 
 
Conclusion 
Treatment of individuals with severe bronchiectasis, chronically infected by 
Pseudomonas aeruginosa, with atorvastatin (80mg daily) for 3 months did not reduce 
cough severity when compared to placebo. However, treatment did improve reported 
quality of life and significantly reduce systemic inflammation. This study confirms 
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the efficacy of atorvastatin as an anti-inflammatory agent in this clinical population 
and justifies larger multicentre studies.  
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e-Appendix 1. 
Procedures 
I. Clinical Studies 
We conducted assessments at baseline, 3 months, 4.5 months and at 7.5 months. 
We assessed cough with the LCQ. This questionnaire is a 19-item, self-completed, quality-of-life 
measure of chronic cough, with scores from 3 to 21 (a lower score indicates more severe cough). 
The minimum clinically important difference in LCQ score is 1·3 units. The LCQ is repeatable over 6 
months in stable disease (intraclass correlation coefficient 0·96, 95% CI 0·93–0·97; p<0·0001) 
(16). 
We measured prebronchodilator FEV1, FVC, and FEV1:FVC by spirometry, followed by an 
incremental shuttle-walk test; an externally paced, 10 m, field-walking test incorporating an 
assessment of dyspnoea before and after, with results recorded on the Borg scale (a rating of 
perceived exertion) (17). Health-related quality of life was assessed with the SGRQ. This 
questionnaire is a 50-item self-administered test with a total score ranging from 0 to 100 (a higher 
score indicates poorer health-related quality of life). The minimum clinical important difference in 
SGRQ score is 4 units (18). 
We induced sputum with hypertonic (3%) saline for 10 min  and gathered samples for 
bacteriological analysis and neutrophil assessments (19). We determined samples as being suitable 
for processing if more than 25 polymorphonuclear leucocytes and fewer than ten squamous cells 
were present on Gram stain with low-power magnification (×20). We used 1 mL of the sputum 
sample for qualitative and quantitative microbiological analyses. Briefly, we homogenised sputum 
and liquefied it with an equal volume of dithiothreitol. To achieve dilution factors of 10−1 to 10−4, 
we serially diluted the liquid samples with sterile 0·85% saline. We inoculated plates of 
Pseudomonas isolation agar (Difco; BD Biosciences, Oxford, UK), chocolate blood agar containing 
bacitracin (Oxoid, Basingstoke, UK), and horse blood agar (Oxoid) with 100 µL of each dilution and 
incubated plates at 37°C for 48 h. We counted colonies of pathogens to ascertain the sputum 
bacterial density (expressed as log10 colony-forming units [cfu] per mL). 
We divided the remainder of the sputum sample equally into two portions. To assess total cell 
numbers, we treated one part with 0·1% Sputolysin (Calbiochem, Hertfordshire), washed the 
sample twice with phosphate-buffered saline, centrifuged it at 2000 g for 10 min at 4°C, and 
filtered the sample once, then did cytocentrifugation at 75 g for 3 min at room temperature. We 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
	  
Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
calculated cell-differential counts by counting 400 cells per sample after cytocentrifugation (20). 
We confirmed apoptosis by the colour and shape change of the neutrophil nuclei on cytospins of 
sputum samples, as observed under light microscopy (magnification ×1000). The second portion 
was ultracentrifuged at 50,000 g for 90 min at 4°C (21). The colloidal solution phase was stored at 
−70°C until needed for analysis of the activity of myeloperoxidase, free neutrophil elastase, and 
CXCL8. We measured myeloperoxidase activity (22) with a chromogenic substrate assay and free 
elastase activity by spectrophotometry with a synthetic substrate (methoxysuccinyl-Ala-Ala-Pro-Val 
paranitroanilide; Sigma, Gillingham, UK), and we assayed interleukin 8 using commercially 
available specific ELISAs (R&D Systems, Oxford, UK) (21,23). 
We took 30 mL of venous blood to obtain a full-blood count; to measure the erythrocyte 
sedimentation rate; to ascertain amounts of C-reactive protein, urea, electrolytes, and creatine 
kinase; and to do liver-function tests. We centrifuged 5 mL of blood at 750 g for 10 min, collected 
the supernatant, and stored it at −70°C until it was needed for measurement of amounts of 
proinflammatory and anti-inflammatory cytokines and chemoattractants by cytometric bead array 
(BD Biosciences) and ELISA’s as per manufacturers protocols (CXCL8 and ICAM 1- R&D systems). 
We assessed patients for the presence or absence of side-effects at all study visits. If activity of 
alanine aminotransferase was greater than five times the normal value, or concentrations of 
creatine kinase were greater than three times the upper limit of normal, we stopped the assigned 
study treatment. We recorded all side-effects on a patient diary card. We defined exacerbations 
according to British Thoracic Society guidelines and treated them according to baseline sputum 
bacteriological findings and administered 14 days of oral antibiotic treatment.  
II. In vitro studies 
Isolation of neutrophils: Freshly drawn blood was collected from healthy volunteers, into 3.8% 
sodium citrate. Granulocytes were subsequently isolated by dextran sedimentation and 
discontinuous Percoll gradient, as described (24). Cells were re suspended at desired 
concentrations in media and counted using a haemocytometer. Purity of neutrophil preparations 
were evaluated by cytocentrifuge preparation analysis and only >95% pure neutrophil populations 
were used in experiments. 
Neutrophil activation: As there was a reduction in serum ICAM-1 (see results section), we 
investigated the role of statins in CD11b expression, which functionally regulates neutrophil 
adhesion. We also assessed expression of CD62L which is key for leukocyte rolling prior to 
migration. After isolation of neutrophils as described above, neutrophils (107/ml in 75 µL PBS 
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containing Ca
2+
/Mg
2+
) in 2 ml eppendorf tubes, atorvastatin (at final concentrations of 1 nM, 10 
nM, 100 nM, 1 µM and 10 µM) was added and kept at 37°C for 30 minutes. Next the eppendorf 
tubes were put on a 37°C shaking heat block (300 rpm), before 100 nM formyl methyl leucyl 
phenylalanine (fMLF) or PBS was added, and incubated for a further 30 minutes. FITC- labelled 
CD11b antibodies and PE- labelled CD62L antibodies were added for 30 minutes and kept on ice in 
the dark. The supernatants were discarded and the cell pellets were resuspended and samples 
analysed by flow cytometry (25). 
Intracellular calcium flux: As Ca2+ ions serve as important second messengers in signal 
transduction in neutrophils, we investigated the role of statins in regulating neutrophil calcium flux.  
Neutrophils were loaded with fura-2/AM (2 µM; Invitrogen) for 30 min in HBSS without divalent 
cations, washed, and re suspended at 2 x 106/ml in HBSS with divalent cations. Intracellular 
calcium flux was quantified using a spectrofluorimeter (Perkin Elmer, Waltham, MA, USA), in 
response to fMLF, with or without a 30 min pretreatment with atorvastatin at varying 
concentrations,  as described (26).  
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